New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
06:57 EDTCBST, IRWD, ACRX, SLXP, BCRX, QCOR, KERX, AUXLBiotech weakness a buying opportunity, says Mizuho
Mizuho said the recent weakness in biotech will prove transient and has created buying opportunities in AcelRx (ACRX), Auxilium (AUXL), BioCryst (BCRX), Ironwood (IRWD), Keryx (KERX), Salix (SLXP), Cubist (CBST), and Questcor (QCOR).
News For ACRX;AUXL;BCRX;IRWD;KERX;SLXP;CBST;QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
07:55 EDTKERXKeryx survey results positive, says Oppenheimer
After surveying 50 nephrologists/nurses/dietitians at U.S. dialysis clinics, Oppenheimer reported that dialysis providers it surveyed expect to prescribe Keryx's Auryxia in 11% of new starts and about 12% of switchers . As a result of this data points and other data from the survey, the firm expects Auryxia prescription trends to improve. It keeps an $18 price target and Outperform rating on the shares.
March 19, 2015
10:42 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
March 18, 2015
10:00 EDTSLXPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:12 EDTAUXLInnocoll appoints James Tursi, M.D., as Chief Medical Officer
Subscribe for More Information
05:45 EDTSLXPSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information
March 16, 2015
16:28 EDTSLXPOn The Fly: Closing Wrap
Subscribe for More Information
12:43 EDTSLXPOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday after stimulus talk out of China and a rally in European stock markets lifted the U.S. market at the open. There was little reaction to the day’s domestic economic reports, which included the Empire manufacturing index, industrial production data, and a homebuilder confidence index. The week's big economic news, however, is yet to come, as investors look forward to the conclusion of the Federal Reserve's latest rate setting meeting on Wednesday. ECONOMIC EVENTS: In the U.S., the Empire State manufacturing index dipped to 6.9 in March, versus the consensus forecast for a reading of 8.0. Industrial production edged up 0.1% in February, versus expectations for an increase of 0.2%, and capacity utilization fell to 78.9%, versus the 79.5% consensus forecast. The NAHB homebuilder sentiment index dropped to 53 in March from 55 in February, missing expectation for the index to rise to 56. Oil prices continued to tumble, with U.S. crude dropping to a six-year low below $44 per barrel earlier in the session. In Asia, Chinese Premier Li Keqiang said Sunday that his government has room and the tools to take action should growth falter, without detailing specific remedies the government might pursue. COMPANY NEWS: Valeant (VRX), which not long ago lost out to Actavis (ACT) in the race to buy Allergan (AGN), increased its chances of making sure its latest buyout deal gets done by increasing its takeover offer to Salix Pharmaceuticals (SLXP) by about $1B. Rival bidder Endo Health (ENDP) confirmed that it is withdrawing its cash and stock proposal to acquire Salix after Valeant raised its all-cash bid for Salix to $173 per share from $158 per share. Shares of Valeant and Salix both rose about 2%, while Endo shares gained 2.5% following the announcements. MAJOR MOVERS: Among the notable gainers was Life Time Fitness (LTM), which rose 5% after entering into a definitive agreement to be acquired by private equity firms Leonard Green & Partners and TPG in a transaction valued at more than $4B, or $72.10 per share, in cash. Also higher was Edwards Lifesciences (EW), which rose 8% after the company reported data at this weekend's American College of Cardiology conference. Among the noteworthy losers was iDreamSky (DSKY), which dropped more than 25% after the company lowered its guidance because the launch of a popular casual game was delayed on one of the company distribution platforms and the monetization of another popular casual game was less than expected. Also lower were shares of Enzo Biochem (ENZ), which fell 17% after an appeals court reversed-in-part and vacated-in-part the judgment in Enzo’s favor that Life Technologies' (LIFE) Applera Corp. infringed certain Enzo patents. INDEXES: Near midday, the Dow was up 174.81, or 0.98%, to 17,924.12, the Nasdaq was up 39.80, or 0.82%, to 4,911.55, and the S&P 500 was up 20.07, or 0.98%, to 2,073.47.
12:18 EDTSLXPProgenics Relistor SI royalty loss transient, says Brean Capital
Subscribe for More Information
10:58 EDTSLXPValeant price hike likely ends Salix saga, says UBS
UBS believes the race for Salix (SLXP) is likely over now that Valeant (VRX) has increased its offer price, as expected. The firm said it will still like both Valeant (VRX) and Endo (ENDP) if this is how things end, as it believes the deal is still a very good one for Valeant despite the higher price and it expects Endo to find another deal that should be accretive. UBS has Buy ratings on both Valeant and Endo Health.
10:18 EDTSLXPValeant should win Salix with increased offer, says Cantor
Subscribe for More Information
10:07 EDTSLXPHigh option volume stocks
Subscribe for More Information
09:24 EDTSLXPEndo withdraws proposal for Salix
Subscribe for More Information
09:22 EDTSLXP, ACRXOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTSLXPValeant rises 1% after sweetening Salix takeover offer
Subscribe for More Information
08:06 EDTSLXPValeant ses Salix deal closing on April 1
08:05 EDTSLXPValeant raises offer price for Salix to $173 per share from $158
Subscribe for More Information
08:04 EDTSLXPValeant, Salix agree on amended terms to merger agreement
Subscribe for More Information
07:50 EDTSLXPSalix trading halted, pending news
Subscribe for More Information
07:50 EDTSLXPValeant to raise offer for Salix to $173 per share, DJ reports
Dow Jones cites sources.
07:01 EDTACRXAcelRx initiates Phase 3 trial for ARX-04
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use